Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff
Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.
Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events. This story matters for Finance & Markets readers tracking bond. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. BondNews.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily bond signal